Across TCGA pan-cancer cohorts, NPM1P30 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated NPM1P30 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPM1P30 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPM1P30 expression acts as an unfavorable survival marker, although some lineages such as COAD and GBM show a favorable association.
LIHC, OV, and LUSC are the cancer types where NPM1P30 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.